Search
Research
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of MedulloblastomaMedulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy and chemotherapy act through the induction of DNA damage, the sensitization of cancer cells through the inhibition of DNA damage repair pathways is a potential therapeutic strategy.
Research
Challenges to curing primary brain tumoursThe seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment in brain tumours
Research
Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group StudyDNA methylation array profiling for classifying pediatric central nervous system (CNS) tumors is a valuable adjunct to histopathology. However, unbiased prospective and interlaboratory validation studies have been lacking. The AIM BRAIN diagnostic trial involving 11 pediatric cancer centers in Australia and New Zealand.
Research
Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumorsNick Raelene Gottardo Endersby MBChB FRACP PhD BSc (Hons) PhD Co-Head, Brain Tumour Research Brainchild Fellow; Co-Head, Brain Tumour Research
Research
BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experienceThe mitogen-activated protein kinase (MAPK) pathway signaling pathway is one of the most commonly mutated pathways in human cancers. In particular, BRAF alterations result in constitutive activation of the rapidly accelerating fibrosarcoma-extracellular signal-regulated kinase-MAPK significant pathway, leading to cellular proliferation, survival, and dedifferentiation.
Research
SNO-EANO-EURACAN consensus on management of pineal parenchymal tumorsPineal parenchymal tumors are rare neoplasms for which evidence-based treatment recommendations are lacking. These tumors vary in biology, clinical characteristics, and prognosis, requiring treatment that ranges from surgical resection alone to intensive multimodal antineoplastic therapy.
Research
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responsesHigh-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where current treatment modalities offer limited efficacy. Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising strategy, boasting tumor-specific targeting and the unique ability to penetrate the blood-brain barrier.
Research
Chemotherapy increases amenability of surgical resection in congenital glioblastomaBrain tumors presenting in infancy, especially during the first 6 months of life.
Research
Pediatric meningioma: Current approaches and future directionWith improvement in leukemia therapy, central nervous system (CNS) tumors are the leading cause of cancer mortality in children and the most expensive...
Research
Diffuse Intrinsic Pontine GliomaThis chapter summarizes recent advances in diffuse intrinsic pontine glioma and potential novel therapies